Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment?

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 5, 2012, Pages 400-408

  Carey, I M ^a   DeWilde, S ^a   Shah, S M ^a   Harris, T ^a   Whincup, P H ^a   Cook, D G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Compliance; Initiation; Myocardial infarction; Persistence; Primary care; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FACTUAL DATABASE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; SEXUAL DEVELOPMENT; SMOKING; SOCIAL ISOLATION; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PSYCHOSOCIAL DEPRIVATION; RECURRENCE; SEX CHARACTERISTICS; SMOKING;

EID: 84859953603     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.09.010     Document Type: Article

References (32)

1. DeWilde S., Carey I.M., Bremner S.A., Richards N., Hilton S.R., Cook D.G. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. Heart 2003, 89:417-421.
2. DeWilde S., Carey I.M., Richards N., Whincup P.H., Cook D.G. Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. Heart 2008, 94:83-88.
3. Helin-Salmivaara A., Lavikainen P.T., Korhonen M.J., Halava H., Martikainen J.E., Saastamoinen L.K., et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care 2010, 16:116-122.
4. Choudhry N.K., Setoguchi S., Levin R., Winkelmayer W.C., Shrank W.H. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf 2008, 17:1189-1196.
5. van der Elst M.E., Bouvy M.L., de Blaey C.J., de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clin Ther 2005, 27:1806-1814.
6. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyörälä K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
7. Pedersen T.R. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
8. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003, 326:1423-1427.
9. Apikoglu R.S., Izzettin F.V., Sancar M., Karakaya O., Kargin R., Yakut C. Five-year follow-up of drug utilization for secondary prevention in coronary artery disease. Pharm World Sci 2008, 30:753-758.
10. Chodick G., Shalev V., Gerber Y., Heymann A.D., Silber H., Simah V., et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008, 30:2167-2179.
11. Huser M.A., Evans T.S., Berger V. Medication adherence trends with statins. Adv Ther 2005, 22:163-171.
12. Rasmussen J.N., Gislason G.H., Rasmussen S., Abildstrom S.Z., Schramm T.K., Kober L., et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Commun Heal 2007, 61:1091-1097.
13. Reid F.D.A., Cook D.G., Whincup P.H. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?. Heart 2002, 88:15-19.
14. National health service framework for coronary heart disease 2000, Department of Health, London.
15. Department of Health. General medical services contract. [05.05.10]. http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/GM S/DH_4125637.
16. Carey I.M., Cook D.G., De Wilde S., Bremner S.A., Richards N., Caine S., et al. Developing a large electronic primary care database (Doctors' Independent Network) for research. Int J Med Inf 2004, 73:443-453.
17. Communities and Local Government. Indices of deprivation 2004-summary (revised). [05.05.10]. http://www.communities.gov.uk/archived/publications/communities/indicesd eprivation.
18. Caetano P.A., Lam J.M., Morgan S.G. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006, 28:1411-1424.
19. Hanley J.A., Negassa A., Edwardes M.D.D., Forrester J.E. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003, 157:364-375.
20. Mcnutt L.A., Wu C.T., Xue X.N., Hafner J.P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003, 157:940-943.
21. de Ruijter W., de Waal M.W., Gussekloo J., Assendelft W.J., Blom J.W. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract 2010, 60:47-49.
22. de Ruijter W., de Waal M.W.M., Gussekloo J., Assendelft W.J.J., Blom J.W. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract 2010, 60:47-49.
23. Collins R., Armitage J., Parish S., Sleight P., Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
24. Shah S., Cook D.G. Inequalities in the treatment and control of hypertension: age, social isolation and lifestyle are more important than economic circumstances. J Hypertens 2001, 19:1333-1340.
25. Wei L., Fahey T., MacDonald T.M. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008, 66:110-116.
26. Hudson M., Rahme E., Richard H., Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007, 153:59-65.
27. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Gadsboll N., Buch P., Friberg J., et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006, 27:1153-1158.
28. Ye X., Gross C.R., Schommer J., Cline R., St Peter W.L. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007, 29:2748-2757.
29. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. NICE Technology Appraisal TA94; 2006.
30. Foody J.M., Joyce A.T., Rudolph A.E., Liu L.Z., Benner J.S. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008, 24:1987-2000.
31. Mantel-Teeuwisse A.K., Klungel O.H., Egberts T.C.G., Verschuren W.M.M., Porsius A.J., de Boer A. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Saf 2004, 27:63-70.
32. Shroufi A., Powles J.W. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Commun Heal 2010, 64:109-113.